Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma

1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy does not improve overall survival in comparison to retreatment at 10 year follow-up. 2. Rituximab maintenance therapy is superior to retreatment therapy for freedom of cytotoxic therapy and response duration at 7-year follow-up. Evidence Rating Level: 1 Study Rundown: The RESORT study […]

The post Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma first appeared on 2 Minute Medicine.